New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
17:42 EDTCPHD, RHHBYCepheid says Roche patent suit will not have material adverse impact on results
Cepheid (CPHD) management stated that they have not had the opportunity to review the claim made by Roche (RHHBY) regarding a patent suit filed earlier; however management stated that it is their understanding that the patent has expired. Either way, the lawsuit will not have a material adverse impact on the company's results.
News For CPHD;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
07:38 EDTCPHDCepheid management to meet with Needham
Subscribe for More Information
07:36 EDTCPHDCepheid management to meet with JPMorgan
Meeting to be held in Chicago on August 4 hosted by JPMorgan.
06:36 EDTRHHBYImmunoGen: enrollment in expansion cohort for IMGN853 to complete by year end
Subscribe for More Information
July 30, 2015
09:25 EDTCPHD, RHHBYLeerink life science tools analyst holds an analyst/industry conference call
Life Science Tools & Diagnostics Analyst Leonard, along with Dr. Anami Patel and Dr. Nathan Ledeboer, discuss their perspectives on Point-of-Care molecular tests including the opportunity in virology / microbiology, the threat to traditional lab-based testing and point-of-care instruments on an Analyst/Industry conference call to be held on July 30 at 11 am.
05:57 EDTRHHBYRoche submits filing to FDA for companion diagnostic for NSCLC drug therapy
Roche announced it has submitted the cobas EGFR Mutation Test v2 for Premarket Approval, or PMA, to the FDA, as a companion diagnostic test for AZD9291, an AstraZeneca (AZN) investigational therapy for non-small cell lung cancer patients with an acquired resistant mutation. Patients with non-small cell lung cancer who have adenocarcinoma with tumor containing an EGFR sensitizing mutation show significant benefit from currently available EGFR TKI therapies. However, approximately two-thirds of these patients will relapse and develop drug resistance. In many cases, this resistance is caused by an acquired mutation called T790M. The cobas EGFR v2 test can aid clinicians to appropriately select NSCLC patients who have acquired the T790M mutation and are most likely to benefit from AstraZeneca's novel therapy.
July 28, 2015
07:15 EDTCPHDCepheid product can beat competition, says Wells Fargo
Subscribe for More Information
07:08 EDTRHHBYRoche introduced several diagnostic testing platforms at the AACC 2015
Subscribe for More Information
July 27, 2015
07:19 EDTCPHDCepheid outlook remains positive, says Wells Fargo
Subscribe for More Information
July 24, 2015
10:00 EDTCPHDOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Abaxis (ABAX) downgraded to Hold from Buy at Canaccord... Buffalo Wild Wings (BWLD) downgraded to Neutral from Buy at Dougherty... CF Industries (CF) downgraded on nitrogen outlook at RBC Capital... Capital One (COF) downgraded to Neutral from Overweight at JPMorgan... Cepheid (CPHD) downgraded to Sell from Hold at Evercore ISI... Constant Contact (CTCT) downgraded to Neutral from Outperform at Baird... Equifax (EFX) downgraded to Neutral from Outperform at Baird... Hannover Re (HVRRY) downgraded to Underweight from Neutral at JPMorgan... IAMGOLD (IAG) downgraded to Underperform from Market Perform at Raymond James... MSA Safety (MSA) downgraded to Neutral from Accumulate at Global Hunter... MTU Aero (MTUAY) downgraded to Underperform from Buy at BofA/Merrill... Macy's (M) downgraded to Underweight from Neutral at Atlantic Equities... Sunesis (SNSS) downgraded to Hold from Buy at Cantor... Superior Drilling (SDPI) downgraded to Hold from Buy at Wunderlich... TrueCar (TRUE) downgraded to Equal Weight from Overweight at Stephens... United Rentals (URI) downgraded to Outperform from Top Pick at RBC Capital... WESCO (WCC) downgraded to Equal Weight from Overweight at Stephens.
07:00 EDTCPHDCepheid downgraded to Sell from Hold at Evercore ISI
Subscribe for More Information
05:55 EDTCPHDCepheid price target raised to $72 from $65 at Mizuho
Mizuho analyst Peter Lawson raised his price target for Cepheid to $72 following the company's Q2 results and reiterates a Buy rating on the name. Placements were strong across the board, which is an indication of strong future demand, Lawson tells investors in a post-earnings research note.
July 23, 2015
16:17 EDTCPHDCepheid sees FY15 EPS 25c-29c, consensus (44c)
Sees FY15 revenue $544M-$553M, consensus $551.29M.
16:16 EDTCPHDCepheid reports Q2 EPS ex-items (6c), consensus (21c)
Subscribe for More Information
06:27 EDTRHHBYRoche CEO expects biosimilars in Europe by late 2017, Reuters reports
Subscribe for More Information
05:46 EDTRHHBYRoche expects FY15 sales to grow low- mid-single digits
Expects FY15 core EPS to grow ahead of sales at constant exchange rates. Roche expects to further increase dividend in Swiss francs.
05:45 EDTRHHBYRoche reports 1H15 core EPS CHF 7.22 vs. 7.57 last year
Subscribe for More Information
July 21, 2015
07:05 EDTRHHBYOphthotech names Shima as Chief Scientific Officer, Bjarke as CCO
Subscribe for More Information
July 20, 2015
07:33 EDTRHHBY, CPHDInternational AIDS Society to hold a conference
Subscribe for More Information
06:17 EDTCPHDMizuho sees Q2 earnings beats in Diagnostics space
Subscribe for More Information
05:13 EDTRHHBYRoche expands HIV Global Access Program
Roche announced an expansion to the HIV Global Access Program to include early infant HIV diagnostic testing for low and middle income countries. Roche, in partnership with the Joint United Nations Programme on HIV/AIDS, or UNAIDS, the Clinton Health Access Initiative, or CHAI, UNITAID, the U.S. President's Emergency Plan For AIDS Relief, or PEPFAR, and the Global Fund to fight AIDS, TB and Malaria, is committed to working with the Diagnostics Access Initiative by providing state-of-the-art solutions to achieve the 90-90-90 goal set forth by UNAIDS. Announced in 2014, the HIV Global Access Program is Roche's most recent addition to the AmpliCare Initiative, which launched in 2002 in South Africa.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use